Dual activation by thyrotropin of the phospholipase C and cyclic AMP cascades in human thyroid.

Mol Cell Endocrinol

Institute of Interdisciplinary Research, School of Medicine, Hospital Erasme, Brussels, Belgium.

Published: August 1987

In human thyroid slices prelabeled with myo-[2-3H]inositol, thyrotropin (TSH, 3-30 mU/ml) stimulated IP3, IP2 and IP1 generation over a prolonged time course. The cAMP response was much more sensitive to TSH, peaking between 1 and 5 mU/ml. Forskolin (10(-5) M) and isoproterenol had no effect on basal IP levels, while carbamylcholine (10(-5) M, 10(-4) M) also increased IP accumulation. These data suggest that in the human thyroid, TSH activates a phospholipase C generating IP3 and diacylglycerol independently of the well-known adenylate cyclase stimulation. They validate in the human model a dual mode of action of the hormone previously proposed on the basis of indirect observations.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0303-7207(87)90055-4DOI Listing

Publication Analysis

Top Keywords

human thyroid
12
dual activation
4
activation thyrotropin
4
thyrotropin phospholipase
4
phospholipase cyclic
4
cyclic amp
4
amp cascades
4
human
4
cascades human
4
thyroid human
4

Similar Publications

Early prediction of patient responses to neoadjuvant chemotherapy (NACT) is essential for the precision treatment of early breast cancer (EBC). Therefore, this study aims to noninvasively and early predict pathological complete response (pCR). We used dynamic ultrasound (US) imaging changes acquired during NACT, along with clinicopathological features, to create a nomogram and construct a machine learning model.

View Article and Find Full Text PDF

Although CCL17 has been reported to exert a vital role in many cancers, the related studies in the thyroid carcinoma have never reported. As a chemokine, CCL17 plays a positive role by promoting the infiltration of immune cells into the tumor microenviroment (TME) to influence tumor invasion and metastasis. Therefore, this study is aimed to investigate the association of CCL17 level with potential prognostic value on tumor immunity in the thyroid carcinoma (THCA) based on the bioinformatics analysis.

View Article and Find Full Text PDF

Pluripotent stem cells possess a unique nuclear architecture characterized by a larger nucleus and more open chromatin, which underpins their ability to self-renew and differentiate. Here, we show that the nucleolus-specific RNA helicase DDX18 is essential for maintaining the pluripotency of human embryonic stem cells. Using techniques such as Hi-C, DNA/RNA-FISH, and biomolecular condensate analysis, we demonstrate that DDX18 regulates nucleolus phase separation and nuclear organization by interacting with NPM1 in the granular nucleolar component, driven by specific nucleolar RNAs.

View Article and Find Full Text PDF

Characteristics of Nodular Goitre and Its Correlation With Papillary Thyroid Carcinoma: A Cross-Sectional Study.

Cureus

November 2024

Department of Endocrinology and Metabolism, Linping Campus, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CHN.

Objective To investigate the clinical characteristics of nodular goitre (NG) and the relationship between NG and papillary thyroid carcinoma (PTC). Methods A total of 282 consecutive patients suspicious for thyroid cancer were enrolled. All the patients underwent surgical resection of the thyroid.

View Article and Find Full Text PDF

Hyperthyroidism is a common endocrine disease caused by the production of thyroid hormones in excessive amounts. Propylthiouracil (PTU) is one of the anti-thyroid drugs (ATD) used in the treatment of hyperthyroidism. Rectal PTU should be considered by physicians as a valuable option for managing hyperthyroidism as an alternative route of administration for patients who cannot tolerate oral medications.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!